102 related articles for article (PubMed ID: 10636514)
1. Prognostic factors in early-onset epithelial ovarian cancer: a population-based study.
Schildkraut JM; Halabi S; Bastos E; Marchbanks PA; McDonald JA; Berchuck A
Obstet Gynecol; 2000 Jan; 95(1):119-27. PubMed ID: 10636514
[TBL] [Abstract][Full Text] [Related]
2. p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer.
Eltabbakh GH; Belinson JL; Kennedy AW; Biscotti CV; Casey G; Tubbs RR; Blumenson LE
Cancer; 1997 Sep; 80(5):892-8. PubMed ID: 9307189
[TBL] [Abstract][Full Text] [Related]
3. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
[TBL] [Abstract][Full Text] [Related]
4. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma.
Shahin MS; Hughes JH; Sood AK; Buller RE
Cancer; 2000 Nov; 89(9):2006-17. PubMed ID: 11064359
[TBL] [Abstract][Full Text] [Related]
5. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
6. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma.
Klemi PJ; Pylkkänen L; Kiilholma P; Kurvinen K; Joensuu H
Cancer; 1995 Oct; 76(7):1201-8. PubMed ID: 8630898
[TBL] [Abstract][Full Text] [Related]
7. Epithelial ovarian tumors in the reproductive age group: age is not an independent prognostic factor.
Massi D; Susini T; Savino L; Boddi V; Amunni G; Colafranceschi M
Cancer; 1996 Mar; 77(6):1131-6. PubMed ID: 8635134
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.
Gershenson DM; Deavers M; Diaz S; Tortolero-Luna G; Miller BE; Bast RC; Mills GB; Silva EG
Clin Cancer Res; 1999 Dec; 5(12):4053-8. PubMed ID: 10632339
[TBL] [Abstract][Full Text] [Related]
10. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma.
Levesque MA; Katsaros D; Yu H; Zola P; Sismondi P; Giardina G; Diamandis EP
Cancer; 1995 Mar; 75(6):1327-38. PubMed ID: 7882283
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of p53 immunostaining in epithelial ovarian cancer.
Hartmann LC; Podratz KC; Keeney GL; Kamel NA; Edmonson JH; Grill JP; Su JQ; Katzmann JA; Roche PC
J Clin Oncol; 1994 Jan; 12(1):64-9. PubMed ID: 8270986
[TBL] [Abstract][Full Text] [Related]
12. p21 expression predicts outcome in p53-null ovarian carcinoma.
Rose SL; Goodheart MJ; DeYoung BR; Smith BJ; Buller RE
Clin Cancer Res; 2003 Mar; 9(3):1028-32. PubMed ID: 12631602
[TBL] [Abstract][Full Text] [Related]
13. Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer.
Schildkraut JM; Bastos E; Berchuck A
J Natl Cancer Inst; 1997 Jul; 89(13):932-8. PubMed ID: 9214672
[TBL] [Abstract][Full Text] [Related]
14. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
Laframboise S; Chapman W; McLaughlin J; Andrulis IL
Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of p53 accumulation in epithelial ovarian carcinomas.
Berker B; Dunder I; Ensari A; Cengiz SD
Arch Gynecol Obstet; 2002 Aug; 266(4):205-9. PubMed ID: 12192480
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
Skírnisdóttir I; Seidal T
Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer.
Baekelandt M; Kristensen GB; Nesland JM; Tropé CG; Holm R
J Clin Oncol; 1999 Jul; 17(7):2061. PubMed ID: 10561259
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of serum soluble CD163 level in patients with epithelial ovarian cancer.
No JH; Moon JM; Kim K; Kim YB
Gynecol Obstet Invest; 2013; 75(4):263-7. PubMed ID: 23595052
[TBL] [Abstract][Full Text] [Related]
19. Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.
Alvarez AA; Axelrod JR; Whitaker RS; Isner PD; Bentley RC; Dodge RK; Rodriguez GC
Gynecol Oncol; 2001 Aug; 82(2):273-8. PubMed ID: 11531279
[TBL] [Abstract][Full Text] [Related]
20. ErbB-3 predicts survival in ovarian cancer.
Tanner B; Hasenclever D; Stern K; Schormann W; Bezler M; Hermes M; Brulport M; Bauer A; Schiffer IB; Gebhard S; Schmidt M; Steiner E; Sehouli J; Edelmann J; Läuter J; Lessig R; Krishnamurthi K; Ullrich A; Hengstler JG
J Clin Oncol; 2006 Sep; 24(26):4317-23. PubMed ID: 16896008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
